$8.33
0.95%
Nasdaq, Nov 14, 10:06 pm CET
ISIN
US15687V1098
Symbol
CERT

Certara Stock News

Neutral
Seeking Alpha
10 days ago
Certara, Inc. ( CERT ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants William Feehery - CEO & Director John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Conference Call Participants David Deuchler - Gilmartin Group LLC Daniel Christopher Clark - Leerink Partners LLC, Research Division David Windley - Jefferies LLC, Research Division Matthew He...
Neutral
GlobeNewsWire
11 days ago
RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025.
Neutral
GlobeNewsWire
13 days ago
RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution.
Neutral
GlobeNewsWire
17 days ago
RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
Neutral
GlobeNewsWire
18 days ago
RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution.
Neutral
GlobeNewsWire
28 days ago
RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research.
Positive
Seeking Alpha
about one month ago
Certara posted strong Q1 and Q2 results, with revenue growth and non-GAAP EPS exceeding expectations, driven by biosimulation software and services. Certara's AI-enabled platforms, including the upcoming AI MIDD and CertaraIQ, are positioned as catalysts for sustainable, long-term growth in drug development. Despite a large total addressable market and cost control, Certara faces analyst downgr...
Neutral
GlobeNewsWire
about one month ago
RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close on Thursday, November 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today